Contacts, documents and full notice history are available with a subscription.
Award Notice 2 notices 9 documents

Olopatadine HCL 0.1% Ophthalmic Solution SPE2D222R0117

Solicitation SPE2D222R0117 Copied Notice ID 172ef8534f7745e6b7958d9ad2800173 Copied DEPT OF DEFENSE — DLA TROOP SUPPORT
SAM.gov
Posted
Jan 27, 2026
Deadline
No deadline
Set-aside
None
NAICS
325412
PSC
6505

Summary

AI-generated · Jan 28, 2026

Olopatadine HCL 0.1% Ophthalmic Solution (5 mL bottle) has been awarded with options to extend procurement through three additional years. Modifications to the contract incorporate DoD Class Deviation 2025-O0003 and add multiple compliance clauses, including Drug Supply Chain Security Act language and related security requirements, FAR 52.204-30 and FAR 52.204-27 provisions, as well as prohibitions on certain applications (ByteDance) and other supply-chain security language into the solicitation. A prior modification also adjusted the price effective date and ship date.

Current awardee is Golden State Medical Supply Inc. For bidders, this means any future competition or amendments will require strict adherence to DSCSA and supply-chain security obligations, and readiness to address any resulting price or ship-date adjustments tied to contract modifications.

Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027. Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003. Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026. Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract. Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025. Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract. Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract. Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023. Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle

From Award Notice posted on Jan 27, 2026

Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle. Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23. Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027. Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003. Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025 through February 14, 2026. Modification SPE2D223D0007 P00005 to incorporate FAR 52.204-30 Federal Acquisition Supply Chain Security Act Orders language into solicitation for subject contract. Modification SPE2D223D0007 P00004 to exercise Option Year 1 effective February 15, 2024 through February 14, 2025. Modification SPE2D223D0007 P00003 to incorporate Drug Supply Chain Security Act language into solicitation for subject contract. Modification SPE2D223D0007 P00002 to incorporate clause FAR 52.204-27 Prohibition on a ByteDance Covered Application (JUN 2023) into subject contract. Modification P00001 SPE2D2-23-D-0007 revising the the price effective date and ship date from April 16, 2023 to February 28, 2023. Contract Award for Olopatadine HCL 0.1% Opthtalmic Solution 5ML Bottle

From Award Notice posted on May 04, 2026

Notice history

2
  1. Award Notice Posted Jan 27, 2026
  2. Award Notice LATEST Posted May 04, 2026

Details

Solicitation number SPE2D222R0117
Notice ID 172ef8534f7745e6b7958d9ad2800173
Award number SPE2D223D0007
Notice type Award Notice
Product / Service (PSC) 6505
NAICS 325412
Place of performance Ontario, Canada
Archive date Feb 15, 2028

Award Information

Awardee
1
Total Awarded
$35,242,906.40
Award Date
Feb 15, 2023

Award Notices

Olopatadine HCL 0.1% Ophthalmic Solution View Notice

Posted: Jan 27, 2026

Modification SPE2D223D0007 P00008 to exercise Option Year 3 effective February 15, 2026 through February 14, 2027. Modification SPE2D223D0007 P00007 is modified in accordance with DoD Class Deviation 2025-O0003. Modification SPE2D223D0007 P00006 to exercise Option Year 2 effective February 15, 2025...

Olopatadine HCL 0.1% Ophthalmic Solution View Notice

Posted: May 04, 2026

Modification SPE2D223D0007 P00011 to change the Manufacturer, Place of Performance and NDC for Olopatadine HCL 0.1% Ophthalmic Solution 5ML Bottle. Modification SPE2D223D0007 P00010 to update new POC for Golden State Medical Supply, Inc. cage code 1HT23. Modification SPE2D223D0007 P00008 to exercise...

Awardees

Company Name UEI CAGE Code Location
GOLDEN STATE MEDICAL SUPPLY INC GQLDJJ8AQNN5 1HT23 Camarillo, CA

Contacts

primary
Kyle Lewicki

Email

Phone

secondary
Jason Wray

Email

Phone

Agency

DEPT OF DEFENSE
DEFENSE LOGISTICS AGENCY
TROOP SUPPORT MEDICAL
DLA TROOP SUPPORT

Place of Performance

Ontario, Canada
CAN

Dates

Posted Jan 27, 2026 6 months ago
Last Updated Jan 29, 2026 6 months ago
Awarded Feb 15, 2023 3 years ago